Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP7517 in R/R AML and R/R Higher Risk MDS
NCT04079296Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2019
- Primary completion
- Apr 2023
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 2
01
Overview
A Phase 2 trial of ASP7517 in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), sponsored by Astellas Pharma. Started Sep 2019; status: completed.
02
Drugs
ASP7517
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT04079296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079296.